PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22293202-3	2012	We found that the treatment of MK886 (an inhibitor of 5-LOX) or knockdown of 5-LOX was able to downregulate the expression of NF-kappaB p65 at the mRNA level and decreased the phosphorylation level of inhibitor kappaBalpha (IkappaBalpha) in the cytoplasm of hepatoma HepG2 or H7402 cells, which resulted in the decrease of the level of nuclear NF-kappaB p65.	MK-886	31-36	nuclear factor kappa B subunit 1	Homo sapiens	126-135	
22293202-3	2012	We found that the treatment of MK886 (an inhibitor of 5-LOX) or knockdown of 5-LOX was able to downregulate the expression of NF-kappaB p65 at the mRNA level and decreased the phosphorylation level of inhibitor kappaBalpha (IkappaBalpha) in the cytoplasm of hepatoma HepG2 or H7402 cells, which resulted in the decrease of the level of nuclear NF-kappaB p65.	MK-886	31-36	nuclear factor kappa B subunit 1	Homo sapiens	344-353	
12882972-4	2003	This IkappaBalpha-induced apoA-I increase was blocked by preincubation with MK886, a selective inhibitor of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting that NFkappaB inactivation induces apoA-I through activation of PPARalpha.	MK-886	76-81	nuclear factor kappa B subunit 1	Homo sapiens	186-194	
9609743-5	1998	There was increased IL-8 nuclear factor-kappaB (NF-kappaB) DNA-binding activity after histamine stimulation, and this was inhibited by DPH and MK-886.	MK-886	143-149	nuclear factor kappa B subunit 1	Homo sapiens	48-57